Impact of adjuvant chemotherapy for patients with locally advanced upper tract urothelial carcinoma in real-world clinical practice

Authors

  • Jun Teishima
  • Junichiro Hirata Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital
  • Takuya Toge Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital
  • Riku Uematsu Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital
  • Yoshie Mita Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital
  • Takahiko Yoshii Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital
  • Ichiro Nakamura Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital

DOI:

https://doi.org/10.5489/cuaj.8438

Keywords:

adjuvant chemotherapy, upper tract urothelial carcinoma, radical nephroureterectomy

Abstract

INTRODUCTION: The impact of adjuvant chemotherapy (ACT) using regimens including gemcitabine and platinum on the improvement of the prognosis of patients with locally advanced upper tract urothelial carcinoma (UTUC) has been recently demonstrated. This study aimed to determine the utility of ACT for patients with locally advanced UTUC in real-world clinical practice and the differences in efficacy among regimens.

METHODS: Of 206 UTUC patients who underwent radical nephroureterectomy, 78 were pathologically diagnosed as T3 or higher and/or had pathologically identified lymph node metastasis; 36 in the ACT group and 42 in the non-ACT group were evaluated for patient background, recurrence, and prognosis. In the ACT group, either cisplatin (GC group, 12 cases) or carboplatin (GCa group, 24 cases) was administered as the platinum agent to be combined with gemcitabine.

RESULT: The median patient age in the ACT group and that in the non-ACT group was 71 and 79 years, respectively (p<0.0001). There was no significant difference between these two groups in terms of other patient parameters. The two- and five-year cancer-specific survival (CSS) and the two- and five-year disease-free survival (DFS) for the ACT group were 81.7%, 66.0%, 60.6%, and 56.6%, respectively, and for the non-ACT group were 68.4%, 40.5%, 42.8%, and 29.3%, respectively (p=0.0399 for CSS and p=0.0814 for DFS). There was no significant difference in CSS and DFS between the GC group and GCa group (p=0.9846 and p=0.9389, respectively).

CONCLUSIONS: In real-world clinical practice in Japan, UTUC patients who receive ACT after radical nephroureterectomy may be expected to have better cancer control than those who do not receive ACT.

Downloads

Download data is not yet available.

Author Biography

Jun Teishima

Downloads

Published

2023-09-29

How to Cite

Teishima, J., Hirata, J., Toge, T., Uematsu, R., Mita, Y., Yoshii, T., & Nakamura, I. (2023). Impact of adjuvant chemotherapy for patients with locally advanced upper tract urothelial carcinoma in real-world clinical practice. Canadian Urological Association Journal, 18(1), E32–6. https://doi.org/10.5489/cuaj.8438

Issue

Vol. 18 No. 1 (2024): CUAJ January

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.